The Facility for iPS Cell Therapy (FiT) at CiRA has published a paper in Inflammation and Regeneration on September 2 that describes the iPS Cell Stock it is manufacturing. This Stock consists of clinical-grade cells, including iPS cells, that have been used in multiple operations in Japan. The goal is to manufacture a stock that serves first the entire Japanese and eventually the whole global population. The paper goes on to describe FiT's goals and accomplishments.

• doi: 10.1186/s41232-019-0106-0